Reslizumab (Cinqair)

Indications

Asthma (see Asthma, [[Asthma]])

  • Clinical Efficacy
    • Phase 2 Trials of Reslizumab in Asthma with Peripheral Eosinophilia (Lancet Resp Med, 2015) [MEDLINE]
      • Reslizumab Decreased Asthma Exacerbations
      • Adverse Effects: similar to placebo (although 2 patients experienced anaphylaxis)
    • Phase 3 Trial of Reslizumab in Poorly-Controlled Asthma (Chest, 2016) [MEDLINE]
      • In Overall Population: Reslizumab Did Not Improve FEV1
        • In Subgroup of Patients with Baseline Peripheral Blood Eosinophils <400/μL: Reslizumab Did Not Improve FEV1
        • In Subgroup of Patients with Baseline Peripheral Blood Eosinophils ≥400/μL: Reslizumab Improved FEV1, ACQ-7, Rescue SABA Use

Pharmacology

  • Monoclonal Antibody Against Interleukin-5 (IL-5)

Metabolism

  • xxxx

Administration

  • xxxx

Dose Adjustment

  • Hepatic:
  • Renal:

Adverse Effects

Other Adverse Effects

  • xxx
  • xxx
  • xxx

References

  • Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32. doi: 10.1164/rccm.201103-0396OC. Epub 2011 Aug 18 [MEDLINE]
  • Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 May;3(5):355-66. doi: 10.1016/S2213-2600(15)00042-9. Epub 2015 Feb 23 [MEDLINE]
  • Phase 3 Study of Reslizumab in Patients with Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. Chest. 2016 Mar 24. pii: S0012-3692(16)45715-6. doi: 10.1016/j.chest.2016.03.018 [MEDLINE]